Home / Market News / $PCRX
benzinga Corporate Catalyst Impact 55/100 ● positive

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

Oct 9, 2026, 2:45 PM UTC · Primary ticker $PCRX

RBC Capital has reiterated its 'Sector Perform' rating for Pacira BioSciences and increased its price target from $25 to $36.5. This analyst action suggests a moderately positive outlook for the company's stock, potentially influencing investor sentiment.

RBC Capital analyst Douglas Miehm has maintained a 'Sector Perform' rating on Pacira BioSciences (PCRX) but significantly raised the price target from $25 to $36.5. This action indicates that while the analyst sees the stock performing in line with its sector, there's an increased valuation expectation. This is a moderately positive signal for PCRX investors, as a higher price target often leads to increased investor confidence and potential buying interest. In the short term, this could provide a modest boost to the stock price. Long-term implications depend on whether the company's fundamentals align with this increased valuation. A key opportunity for traders is to consider if this price target adjustment reflects underlying positive developments not yet fully priced into the stock.

$PCRX positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.